Information Provided By:
Fly News Breaks for March 3, 2020
Mar 3, 2020 | 05:02 EDT
Piper Sandler analyst Sean Wieland lowered the firm's price target on Allscripts to $9.50 from $12 and keeps a Neutral rating on the shares. The company missed Q4 revenue estimates and guided 2020 below consensus, Wieland tells investors in a research note. The 2019 results and 2020 guidance render Allscripts's 2019-2021 non-GAAP organic revenue target unachievable, adds the analyst.
News For MDRX From the Last 2 Days
There are no results for your query MDRX